Evidence map›Paper›PMID 42584798›Full record

ArticleBlood research2026

Deciphering the circadian signature in acute myeloid leukemia: NPAS2 downregulation as a master predictive feature.

Leidivan Sousa da Cunha, Guilherme Passos de Morais, Caio Bezerra Machado, Deivide de Sousa Oliveira, Beatriz Maria Dias Nogueira, Anna Karolyna da Costa Machado, Isabelle Magalhães Farias, Flávia Melo Cunha de Pinho Pessoa, Rodrigo Monteiro Ribeiro, Kaira Mara Cordeiro de Alburquerque and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Leidivan Sousa da Cunha *Department of Medicine, Clinical Genetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil.
Guilherme Passos de Morais *Department of Medicine, Clinical Genetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil.
Caio Bezerra MachadoDepartment of Medicine, Clinical Genetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil.
Deivide de Sousa OliveiraDepartment of Medicine, Clinical Genetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil.
Beatriz Maria Dias NogueiraDepartment of Medicine, Clinical Genetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil.
Anna Karolyna da Costa MachadoDepartment of Medicine, Clinical Genetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil.
Isabelle Magalhães FariasDepartment of Medicine, Clinical Genetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil.
Flávia Melo Cunha de Pinho PessoaDepartment of Medicine, Clinical Genetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil.
Rodrigo Monteiro RibeiroDepartment of Hematology, Fortaleza General Hospital (HGF), Fortaleza, CE, Brazil.
Kaira Mara Cordeiro de AlburquerqueDepartment of Hematology, Fortaleza General Hospital (HGF), Fortaleza, CE, Brazil.
Mateus de Paula GomesDepartment of Hematology, Fortaleza General Hospital (HGF), Fortaleza, CE, Brazil.
Manoel Odorico de Moraes FilhoDepartment of Medicine, Clinical Genetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil.
Maria Elisabete Amaral de MoraesDepartment of Medicine, Clinical Genetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil.
Caroline Aquino Moreira-NunesDepartment of Medicine, Clinical Genetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, Brazil. carolfam@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeConsidering the role of circadian clock genes in leukemogenesis through the regulation of cell cycle progression and genomic stability, this study aimed to evaluate the expression of NPAS2, CIPC, BMAL1, and CLOCK in acute myeloid leukemia (AML) and to determine their individual and combined diagnostic performance.

methodsIn this study, bone marrow (BM) and peripheral blood (PB) samples were obtained from newly diagnosed AML patients and healthy controls under standardized circadian conditions. Gene expression was measured by TaqMan RT-qPCR and normalized to ABL using the 2

resultsPB showed comparable expression levels to paired BM samples, supporting its use as a surrogate tissue for circadian biomarker assessment. All transcripts were significantly downregulated in AML compared with controls (p < 0.001), with NPAS2 showing the most pronounced reduction. NPAS2 exhibited the highest diagnostic performance (AUC = 0.925). The random forest classifier achieved 74% sensitivity and 100% specificity, and SHAP analysis identified NPAS2 as the most influential predictive feature.

conclusionAs such, we propose downregulation of NPAS2 as a potential biomarker for diagnosis of AML.

Indexed as

Acute myeloid leukemiaBiomarkersCircadian rhythmClock genes

Identifiers

PMID42584798
PMCPMC13468828

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.